Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | VP of Marketing | April 26, 2021 | April 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date April 26, 2021 · Filed April 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2031-04-26 | Direct | 60,000 |
Reported balance
After 2021-04-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-26 · Grant · Acquired 60,000 · Balance 60,000 F1: 25% will vest on April 26, 2022 and the remaining 75% will vest in 36 equal monthly installments beginning on May 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on April 26, 2022 and the remaining 75% will vest in 36 equal monthly installments beginning on May 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2021 Filed Apr 28, 2021 18:13 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 60,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001859325-21-000002 · primary_doc.xml · derivative · entry 1 Haris Hijaz · CIK 0001859325 · VP of Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: 25% will vest on April 26, 2022 and the remaining 75% will vest in 36 equal monthly installments beginning on May 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.